What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis
Bronte G(1), Rolfo C(2), Passiglia F(1), Rizzo S(1), Gil-Bazo I(3), Fiorentino E(4), Cajozzo M(5), Van Meerbeeck JP(6), Lequaglie C(7), Santini D(8), Pauwels P(9), Russo A(1).
Randomized phase III trials showed interesting, but conflicting results, regarding the treatment of NSCLC, PS2 population. This meta-analysis aims to review all randomized trials comparing platinum-based doublets and single-agents in NSCLC PS2 patients.
MATERIALS AND METHODS:
Data from all published randomized trials, comparing efficacy and safety of platinum-based doublets to single agents in untreated NSCLC, PS2 patients, were collected. Pooled ORs were calculated for the 1-year Survival-Rate (1y-SR), Overall Response Rate (ORR), and grade 3-4 (G3-4) hematologic toxicities.
Six eligible trials (741 patients) were selected. Pooled analysis showed a significant improvement in ORR (OR: 3.243; 95% CI: 1.883-5.583) and 1y-SR (OR: 1.743; 95% CI: 1.203-2.525) in favor of platinum-based doublets. G3-4 hematological toxicities were also more frequent in this group.
This meta-analysis suggests that platinum-combination regimens are superior to singleagent both in terms of ORR and survival-rate with increase of severe hematological toxicities.
CITATION Crit Rev Oncol Hematol. 2015 Apr 11. pii: S1040-8428(15)00066-9. doi: 10.1016/j.critrevonc.2015.03.010.